{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of events for median, upper limit not calculable","groupId":"OG000","lowerLimit":"11.01","upperLimit":"NA","value":"27.04"},{"comment":"Insufficient number of events for median, upper limit not calculable","groupId":"OG001","lowerLimit":"6.90","upperLimit":"NA","value":"24.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Eligible Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Eligible Subgroup"}],"paramType":"MEDIAN","populationDescription":"Platinum eligible subgroup responders","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression or death. Approximately 63 Months","title":"Duration of Response (DOR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Eligible Subgroup","type":"SECONDARY","unitOfMeasure":"Months"}